–01– Introduction Antibody-drug conjugates (ADC) are known as “magic bullets” that precisely target tumor cells through antibodies, delivering cytotoxic drugs while combining the precision of targeted therapy with the potent killing power of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field … Read more
Clinical Development of ADCs for Solid Tumors The currently approved ADCs for solid tumors are listed in the table below: ADCs Target Indications T-DM1 HER2 HER2-positive metastatic breast cancer SG (sacituzumab govitecan) Trop2 Triple-negative breast cancer (TNBC) Metastatic urothelial carcinoma (mUC) sacituzumab tirumotecan Trop2 TNBC, NSCLC Gastric cancer/gastroesophageal junction cancer, mUC enfortumab vedotin Nectin-4 Locally … Read more
At this year’s AACR annual meeting, there were hundreds of details related to ADC drugs. Leading ADC company Daiichi Sankyo announced the latest research progress of its HER3-targeted ADC product Patritumab deruxtecan (HER3-DXd); AstraZeneca also disclosed research updates on several drugs including AZD9592 (bispecific ADC) and AZD5335 (FRα ADC). Many Chinese pharmaceutical companies also showcased … Read more
Synergizing Catalysis with Post-catalysis Pseudo-Iron Release by Building Dynamic Catalytic Active Sites in Diatomic Nanozymes for Boosting Cancer TherapyJournal of the American Chemical Society ( IF 14.4 ) Pub Date : 2025-04-25DOI: 10.1021/jacs.5c03804Diatomic nanozymes have significant potential in tumor therapy, but their therapeutic efficacy is often limited by their low catalytic activity. Here, we propose … Read more
01 DAC‘s Emergence and Advantages Cancer therapeutics need to balance efficacy and safety, even targeted chemotherapy does not always only kill abnormal cancer cells, and non-specific toxicity can lead to a low therapeutic index and side effects. The technology of Proteolysis-targeting chimeras (PROTACs), which achieve therapeutic effects by promoting the degradation of target proteins, is … Read more
After 2019, ADC drugs have been approved for marketing one after another, and the approval of Aidiqi in 2021 marked a milestone in the development of domestic ADC innovative drugs. The broad therapeutic prospects and huge market size have stimulated many pharmaceutical companies to ignite their enthusiasm for ADC drug research and development, leading the … Read more
Introduction Antibodies are one of the key components of ADC drugs, serving as precise guiding components with the functions of targeting and toxin delivery. They can specifically recognize the target antigens on the surface of tumor cells, delivering toxins to the tumor cells and mediating the localization and endocytosis of ADCs in tumor cells[1]. After … Read more
History of ADC Drug Development Phase 1 (1906-1982), the concept of targeted therapy was proposed, and the technology took shape. Phase 2 (1983-2011), transition from clinical trials to commercialization, Mylotarg® was approved for market. Phase 3 (2012-present), explosive growth of ADC products. The five key elements of ADC drugs are target, antibody, linker, cytotoxic agent, … Read more
To improve the DMPK characteristics, many studies have explored the coupling of PROTAC payloads with monoclonal antibodies to create a new molecule known as “Antibody-Drug Conjugates (DAC).” This allows for more effective delivery of PROTAC degraders in vivo. ▲ Structure of DAC (Image Source: Reference 1) Compared to PROTAC molecules, DAC has several potential advantages: … Read more
The Emergence and Advantages of DAC Cancer therapeutics need to achieve a balance between efficacy and safety, even targeted chemotherapy does not always only kill abnormal cancer cells, non-specific toxicity can lead to a low therapeutic index and side effects. The technology of proteolysis-targeting chimeras (PROTACs), which achieves therapeutic effects by promoting the degradation of … Read more